160 related articles for article (PubMed ID: 35188730)
21. Systemic delivery of siRNA by aminated poly(α)glutamate for the treatment of solid tumors.
Polyak D; Krivitsky A; Scomparin A; Eliyahu S; Kalinski H; Avkin-Nachum S; Satchi-Fainaro R
J Control Release; 2017 Jul; 257():132-143. PubMed ID: 27356019
[TBL] [Abstract][Full Text] [Related]
22. Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer.
Zeng L; Li J; Wang Y; Qian C; Chen Y; Zhang Q; Wu W; Lin Z; Liang J; Shuai X; Huang K
Nanomedicine; 2014 Feb; 10(2):463-72. PubMed ID: 24028894
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth.
Liu XQ; Xiong MH; Shu XT; Tang RZ; Wang J
Mol Pharm; 2012 Oct; 9(10):2863-74. PubMed ID: 22924580
[TBL] [Abstract][Full Text] [Related]
24. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
25. Tumoral gene silencing by receptor-targeted combinatorial siRNA polyplexes.
Lee DJ; He D; Kessel E; Padari K; Kempter S; Lächelt U; Rädler JO; Pooga M; Wagner E
J Control Release; 2016 Dec; 244(Pt B):280-291. PubMed ID: 27287890
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer.
Ellermeier J; Wei J; Duewell P; Hoves S; Stieg MR; Adunka T; Noerenberg D; Anders HJ; Mayr D; Poeck H; Hartmann G; Endres S; Schnurr M
Cancer Res; 2013 Mar; 73(6):1709-20. PubMed ID: 23338611
[TBL] [Abstract][Full Text] [Related]
27. Combinatorial siRNA Polyplexes for Receptor Targeting.
Lee DJ; Wagner E
Methods Mol Biol; 2019; 1974():83-98. PubMed ID: 31098997
[TBL] [Abstract][Full Text] [Related]
28. Bioreducible, arginine-rich polydisulfide-based siRNA nanocomplexes with excellent tumor penetration for efficient gene silencing.
Zhang X; Hong K; Sun Q; Zhu Y; Du J
Biomater Sci; 2021 Jul; 9(15):5275-5292. PubMed ID: 34180478
[TBL] [Abstract][Full Text] [Related]
29. [Experimental study of MAT1 gene silencing mediated by siRNA in pancreatic cancer].
Liu JP; Yuan SZ; Zhang SN
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2719-23. PubMed ID: 18167254
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy priming of the Pancreatic Tumor Microenvironment Promotes Delivery and Anti-Metastasis Efficacy of Intravenous Low-Molecular-Weight Heparin-Coated Lipid-siRNA Complex.
Yu Q; Qiu Y; Chen X; Wang X; Mei L; Wu H; Liu K; Liu Y; Li M; Zhang Z; He Q
Theranostics; 2019; 9(2):355-368. PubMed ID: 30809279
[TBL] [Abstract][Full Text] [Related]
31. Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumor-stromal cross-talk.
Averett C; Bhardwaj A; Arora S; Srivastava SK; Khan MA; Ahmad A; Singh S; Carter JE; Khushman M; Singh AP
Carcinogenesis; 2016 Nov; 37(11):1052-1061. PubMed ID: 27609457
[TBL] [Abstract][Full Text] [Related]
32. NGF from pancreatic stellate cells induces pancreatic cancer proliferation and invasion by PI3K/AKT/GSK signal pathway.
Jiang J; Bai J; Qin T; Wang Z; Han L
J Cell Mol Med; 2020 May; 24(10):5901-5910. PubMed ID: 32294802
[TBL] [Abstract][Full Text] [Related]
33. Stimuli-Responsive Polymer-Prodrug Hybrid Nanoplatform for Multistage siRNA Delivery and Combination Cancer Therapy.
Saw PE; Yao H; Lin C; Tao W; Farokhzad OC; Xu X
Nano Lett; 2019 Sep; 19(9):5967-5974. PubMed ID: 31381852
[TBL] [Abstract][Full Text] [Related]
34. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
35. PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo.
Pan X; Zhu Q; Sun Y; Li L; Zhu Y; Zhao Z; Zuo J; Fang W; Li K
Int J Mol Med; 2015 Apr; 35(4):995-1002. PubMed ID: 25672594
[TBL] [Abstract][Full Text] [Related]
36. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.
Zhao X; Li F; Li Y; Wang H; Ren H; Chen J; Nie G; Hao J
Biomaterials; 2015 Apr; 46():13-25. PubMed ID: 25678112
[TBL] [Abstract][Full Text] [Related]
37. [Development of siRNA Delivery Targeting the Tumor Microenvironment with a New Functional Device].
Sakurai Y
Yakugaku Zasshi; 2019; 139(11):1357-1363. PubMed ID: 31685731
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer.
Miwa T; Kokuryo T; Yokoyama Y; Yamaguchi J; Nagino M
Cancer Med; 2015 Jul; 4(7):1091-100. PubMed ID: 25914189
[TBL] [Abstract][Full Text] [Related]
39. Small interfering RNAs targeting mutant K-ras inhibit human pancreatic carcinoma cells growth in vitro and in vivo.
Zhu H; Liang ZY; Ren XY; Liu TH
Cancer Biol Ther; 2006 Dec; 5(12):1693-8. PubMed ID: 17106254
[TBL] [Abstract][Full Text] [Related]
40. Adenovirus vector-mediated Gli1 siRNA induces growth inhibition and apoptosis in human pancreatic cancer with Smo-dependent or Smo-independent Hh pathway activation in vitro and in vivo.
Guo J; Gao J; Li Z; Gong Y; Man X; Jin J; Wu H
Cancer Lett; 2013 Oct; 339(2):185-94. PubMed ID: 23791879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
